- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00465634
Doppler and Biological Second Trimester Placental Insufficiency Screening (ARTULEP)
Screening for Placental Insufficiency by a Combination of Second Trimester Uterine Artery Doppler and Maternal Serum Leptin and Lipids
Study Overview
Status
Detailed Description
Pre-eclampsia (PE) and intrauterine growth restriction (IUGR) are known as major factors in perinatal morbidity and mortality. Routine antenatal care is focused on the detection of women at increased risk to apply this population a program of careful monitoring and appropriate intervention.
Uterine artery Doppler during anomaly scan at 20 to 24 weeks in selected women at increased risk, has proved to be accurate to detect those who will develop PE or IUGR during the second half of pregnancy. Studies have reported detection rate of 50-70% for a 5% false positive rate in women developing early pre-eclampsia.
A variety of proteins and hormones have been studied as potential markers for pre-eclampsia. Among these protein serum placental leptin has demonstrated higher levels in pregnant women who will subsequently develop pre-eclampsia. However, screening performance of leptin detection in early pregnancy has never been assessed.
Our study is aimed to evaluate the performance of serum leptin measurement in association with uterine artery Doppler as a screening too for placental insufficiency.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Tours, France, 37044
- Olympe de Gouges Women Health Centre, Bretonneau University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Chronic hypertension under medication
- Diabetes
- Thrombophilia
- Previous history of pre-eclampsia
- Previous history of unexplained stillbirth
- Previous history of placental abruption
- Previous history of SGA (< 10th centile)
- History of pre-eclampsia or chronic hypertension before 45 years in the mother or a sister
- Obesity (BMI>30)
- Nulliparous after 40 years
- Assisted conception with donor
Exclusion Criteria:
- Multiple pregnancy
- Complicated pregnancy with a high probability of required fetal extraction before term
- Pregnancy requiring termination
- Unability to understand the study
Study Plan
How is the study designed?
Design Details
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Franck Perrotin, MD-PhD, Tours University Hospital
Publications and helpful links
General Publications
- Papageorghiou AT, Leslie K. Uterine artery Doppler in the prediction of adverse pregnancy outcome. Curr Opin Obstet Gynecol. 2007 Apr;19(2):103-9. doi: 10.1097/GCO.0b013e32809bd964.
- Guven MA, Ertas IE, Kilinc M, Coskun A, Ekerbicer H. Combining mid-trimester maternal plasma homocysteine with uterine artery doppler velocimetry: is it useful? Arch Gynecol Obstet. 2007 Jun;275(6):439-43. doi: 10.1007/s00404-006-0281-5. Epub 2006 Nov 17.
- Spencer K, Yu CK, Savvidou M, Papageorghiou AT, Nicolaides KH. Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy-associated plasma protein-A, free beta-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation. Ultrasound Obstet Gynecol. 2006 Jun;27(6):658-63. doi: 10.1002/uog.2676.
- Tommaselli GA, Pighetti M, Nasti A, D'Elia A, Guida M, Di Carlo C, Bifulco G, Nappi C. Serum leptin levels and uterine Doppler flow velocimetry at 20 weeks' gestation as markers for the development of pre-eclampsia. Gynecol Endocrinol. 2004 Sep;19(3):160-5. doi: 10.1080/09513590400007267.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PHRR02-FP/ARTULEP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pre-Eclampsia
-
Amsterdam UMCZonMw: The Netherlands Organisation for Health Research and DevelopmentNot yet recruitingPre-Eclampsia | HELLP Syndrome | Pre-eclampsia or Eclampsia With Pre-existing Hypertension | HELLP | Pre-Eclampsia; Complicating Pregnancy | Pre-Eclampsia Onset Less Than 37 Weeks | Pre-Eclampsia as Antepartum Condition | Pre-Eclampsia; Affecting Fetus | HELLP Syndrome Complicating Pregnancy
-
Assiut UniversityNot yet recruitingPre-eclampsia Aggravated | Pre-Eclampsia; Complicating Pregnancy
-
Dow University of Health SciencesCompletedPre-eclampsia | Hypertension, Pregnancy Induced | Hydralazine Adverse Reaction | Pre-eclampsia Superimposed Pre-existing HypertensionPakistan
-
University of WashingtonUniversity of Cape TownCompletedSevere Pre-eclampsia | Mild Pre-eclampsiaSouth Africa, United States
-
William Marsh Rice UniversityUniversity of MalawiCompleted
-
Duke UniversityTerminated
-
William Marsh Rice UniversityCompletedPre EclampsiaUnited States
-
Oxford University Hospitals NHS TrustUniversity of CambridgeTerminated
-
Novartis PharmaceuticalsTerminatedPre-eclampsiaItaly, United States
-
Far Eastern Memorial HospitalGynecologic Oncology GroupRecruiting